Logo image of AERI

AERIE PHARMACEUTICALS INC (AERI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AERI - US00771V1089 - Common Stock

15.25 USD
+0.01 (+0.07%)
Last: 11/18/2022, 8:21:01 PM
15.25 USD
0 (0%)
After Hours: 11/18/2022, 8:21:01 PM
Fundamental Rating

2

Taking everything into account, AERI scores 2 out of 10 in our fundamental rating. AERI was compared to 192 industry peers in the Pharmaceuticals industry. AERI may be in some trouble as it scores bad on both profitability and health. AERI is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AERI had negative earnings in the past year.
AERI had a positive operating cash flow in the past year.
AERI Yearly Net Income VS EBIT VS OCF VS FCFAERI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -9.73%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AERI Yearly ROA, ROE, ROICAERI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 400 -400 -600

1.3 Margins

Industry RankSector Rank
OM -12.49%
PM (TTM) -17.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AERI Yearly Profit, Operating, Gross MarginsAERI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

AERI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AERI has been increased compared to 1 year ago.
Compared to 1 year ago, AERI has a worse debt to assets ratio.
AERI Yearly Shares OutstandingAERI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
AERI Yearly Total Debt VS Total AssetsAERI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.71, we must say that AERI is in the distress zone and has some risk of bankruptcy.
AERI has a debt to FCF ratio of 118.54. This is a negative value and a sign of low solvency as AERI would need 118.54 years to pay back of all of its debts.
A Debt/Equity ratio of -1.91 indicates that AERI is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -1.91
Debt/FCF 118.54
Altman-Z -2.71
ROIC/WACCN/A
WACC8.3%
AERI Yearly LT Debt VS Equity VS FCFAERI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M -100M 200M

2.3 Liquidity

AERI has a Current Ratio of 2.27. This indicates that AERI is financially healthy and has no problem in meeting its short term obligations.
AERI has a Quick Ratio of 1.92. This is a normal value and indicates that AERI is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.92
AERI Yearly Current Assets VS Current LiabilitesAERI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.48% over the past year.
The Revenue has grown by 105.42% in the past year. This is a very strong growth!
The Revenue has been growing by 100.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%

3.2 Future

AERI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.85% yearly.
Based on estimates for the next years, AERI will show a very strong growth in Revenue. The Revenue will grow by 21.90% on average per year.
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AERI Yearly Revenue VS EstimatesAERI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
AERI Yearly EPS VS EstimatesAERI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AERI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AERI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AERI Price Earnings VS Forward Price EarningsAERI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF 285.78
EV/EBITDA -38.22
AERI Per share dataAERI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as AERI's earnings are expected to grow with 24.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y24.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AERI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AERIE PHARMACEUTICALS INC

NASDAQ:AERI (11/18/2022, 8:21:01 PM)

After market: 15.25 0 (0%)

15.25

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2022-11-03/amc
Earnings (Next)02-22 2023-02-22
Inst Owners4.85%
Inst Owner Change0%
Ins Owners2.91%
Ins Owner Change0%
Market Cap753.62M
Revenue(TTM)213.94M
Net Income(TTM)-36.55M
Analysts71.43
Price Target15.63 (2.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.81%
Min EPS beat(2)39.47%
Max EPS beat(2)44.16%
EPS beat(4)4
Avg EPS beat(4)85.81%
Min EPS beat(4)0.99%
Max EPS beat(4)258.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)0.62%
Revenue beat(4)2
Avg Revenue beat(4)63.94%
Min Revenue beat(4)-2.07%
Max Revenue beat(4)257.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.52
P/FCF 285.78
P/OCF 105.15
P/B N/A
P/tB N/A
EV/EBITDA -38.22
EPS(TTM)-0.16
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)0.05
FCFY0.35%
OCF(TTM)0.15
OCFY0.95%
SpS4.33
BVpS-3.32
TBVpS-3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -12.49%
PM (TTM) -17.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity -1.91
Debt/FCF 118.54
Debt/EBITDA N/A
Cap/Depr 70.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.92
Altman-Z -2.71
F-Score5
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)97.96%
Cap/Depr(5y)541.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Sales Q2Q%23.25%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%
EBIT growth 1Y80.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.26%
EBIT Next 3Y27.69%
EBIT Next 5Y14.97%
FCF growth 1Y102.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.28%
OCF growth 3YN/A
OCF growth 5YN/A

AERIE PHARMACEUTICALS INC / AERI FAQ

What is the fundamental rating for AERI stock?

ChartMill assigns a fundamental rating of 3 / 10 to AERI.


Can you provide the valuation status for AERIE PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to AERIE PHARMACEUTICALS INC (AERI). This can be considered as Overvalued.


Can you provide the profitability details for AERIE PHARMACEUTICALS INC?

AERIE PHARMACEUTICALS INC (AERI) has a profitability rating of 4 / 10.


Can you provide the financial health for AERI stock?

The financial health rating of AERIE PHARMACEUTICALS INC (AERI) is 2 / 10.


What is the expected EPS growth for AERIE PHARMACEUTICALS INC (AERI) stock?

The Earnings per Share (EPS) of AERIE PHARMACEUTICALS INC (AERI) is expected to decline by -85.62% in the next year.